EGFR and non-small cell lung carcinoma: In addition, according to current guidelines for clinical practice, EGFR‐tyrosine kinase inhibitor (TKI) is recommended as the first choice of therapy in the patients with advanced‐stage NSCLC, harboring EGFR mutations.7, 8, 9